✓
Open
26 Aug 2025
✓
Close
29 Aug 2025
3
Allotment
—
✓
Listing
Wed, Sep 3, 2025
Price Band
₹86 to ₹91
Issue Size
1,33,00,000 shares (agg. up to ₹121 Cr)
Lot Size
164 Shares
Listing Date
Wed, Sep 3, 2025
Latest GMP
₹1
Est. Gain
1.1%
✦ AI Insight
GMP Trend
03-09-2025₹1Est. ₹92+1.1%
02-09-2025₹1Est. ₹92+1.1%
01-09-2025₹2Est. ₹93+2.2%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 6.95x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| NET Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,452.90 (-1.74%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,294.90 (+2.45%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹73.50 (-2.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹290.00 (-0.60%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹283.00 (-1.57%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹166.00 (+3.33%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹42.11 (+2.71%) |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹130.00 (-1.59%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹39.55 (+4.91%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for Proposed Expansion | 30.72 |
| 2 | Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company | 5.00 |
| 3 | Funding the working capital requirements of the Company | 43.15 |
| 4 | General Corporate Purposes | 27.03 |
| 5 | Issue Expenses | 15.13 |
| Total | 121.03 |
About Anlon Healthcare IPO
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products). The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP. In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs. The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. The company ensures product quality through rigorous te
Contact Details
Anlon Healthcare Ltd. Address101/102, Silvercoin ComplexOpp.Crystal MallKalawad RoadRajkot, Gujarat, 360005+91 281 2562538cs@anloncro.comVisit Website